CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
NEWARK, Calif., April 13, 2017 -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for specialty and orphan diseases with high unmet medical need, today announced that data from its Phase 2 proof-of-concept study of seladelpar in patients with primary biliary cholangitis (PBC) will be presented at the International Liver CongressTM 2017 sponsored by the European Association for the Study of Liver Diseases (EASL), in Amsterdam, The Netherlands, April 19-23 2017. Seladelpar is an orally administered potent and selective peroxisome proliferator-activated receptor delta (PPARδ) agonist.
| Title: | Proof of efficacy for seladelpar, a selective PPARδ agonist, in patients with primary biliary cholangitis non-responsive to ursodeoxycholic acid: results of an international Phase 2 randomised controlled clinical study |
| Abstract: | FRI-378 |
| Session: | Oral ePosters, Autoimmune and cholestatic liver disease (clinical) |
| Date: | April 22, 2017 |
| Time: | 13:00 – 14:00 |
| Location: | Poster Booth 1 (Hall 1) |
| Authors: | G.M. Hirschfield, M.R. Galambos, C.L. Bowlus, M.G. Swain, Y. Doerffel, A.S. Steinberg, M. Varga, Y.-J. Choi, R.L. Martin, H. Chera, C.A. McWherter, P.F. Boudes, and D. Jones for the MBX8025-21528 Study Investigators |
”We are very pleased that EASL has selected our clinical work on seladelpar to be presented at the premier international hepatic congress. This provides us a great opportunity to present new data concerning the mechanism of action of seladelpar to improve the cholestasis affecting patients with PBC,” said Pol Boudes, MD, Chief Medical Officer of CymaBay Therapeutics. Dr. Boudes added, “We are truly grateful to our investigators and their patients and want to thank them for their invaluable contribution.”
About PBC
Primary biliary cholangitis (PBC) is a serious and potentially life threatening autoimmune disease of the liver characterized by impaired bile flow (cholestasis) and accumulation of toxic bile acids. There is an accompanying inflammation and destruction of the intrahepatic bile ducts, which can progress to fibrosis, cirrhosis and liver failure. Other clinical symptoms of PBC include fatigue and pruritus, which can be quite disabling in some patients. PBC is primarily a disease of women, afflicting approximately one in 1,000 over the age of 40.
About Seladelpar
Seladelpar is a potent, selective, orally active PPARδ agonist that is in development for the treatment of the liver diseases PBC and NonAlcoholic SteatoHepatitis (NASH). For PBC, seladelpar has received an orphan designation from the US Food and Drug Administration and the PRIority Medicine (PRIME) status from the European Medicine Agency.
About CymaBay
CymaBay Therapeutics, Inc. (CBAY) is a clinical-stage biopharmaceutical company focused on developing therapies for specialty and orphan diseases with high unmet medical need. Seladelpar is a potent, selective, orally active PPARδ agonist. A Phase 2 study of seladelpar in patients with mixed dyslipidemia established that it has an anti-atherogenic lipid profile. CymaBay has completed Phase 2 studies for seladelpar in subjects with primary biliary cholangitis and homozygous familial hypercholesterolemia, establishing proof-of-concept in both indications. Arhalofenate is a potential Urate-Lowering Anti-Flare Therapy that has completed five Phase 2 studies in subjects with gout. Arhalofenate has been found to reduce painful flares in joints while at the same time lowering serum uric acid by promoting excretion of uric acid by the kidney. This dual action addresses both the signs and symptoms of gout while managing the underlying pathophysiology of hyperuricemia. Arhalofenate has been licensed in the U.S. to Kowa Pharmaceuticals America, Inc. CymaBay retains full development and commercialization rights for arhalofenate outside the U.S.
For additional Information about CymaBay visit www.cymabay.com.
Contacts: Sujal Shah CymaBay Therapeutics, Inc. (510) 293-8800 [email protected] Hans Vitzthum LifeSci Advisors, LLC 212-915-2568 [email protected]
